![]()
|
|
||||||||
(Received for publication, February 15, 1996, and in revised form, July 11, 1996)
From the Research Division, Joslin Diabetes Center, Department of
Medicine, Brigham and Women's Hospital, and Harvard Medical
School, Boston, Massachusetts 02215
We have reported previously that substitution of
the transmembrane domain of the insulin receptor with that of the
erbB-2 oncogene (IRerbV In contrast to IRerbV
Volume 271, Number 45,
Issue of November 8, 1996
pp. 28206-28211
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
E) results in
constitutive activation of the insulin receptor kinase. Compared to
NIH3T3 cells overexpressing wild-type insulin receptors
(IRwt), cells overexpressing IRerbV
E
displayed a decrease in IRS-1 protein content by 55%, but basal
tyrosine phosphorylation of IRS-1 was increased. This resulted in an
increased association of IRS-1 with the p85 subunit of
phosphatidylinositol 3-kinase, increased phosphatidylinositol 3-kinase
activity in anti-IRS-1 immunoprecipitates, constitutive activation of
p70 S6 protein kinase, and an increased association of Grb2 with Shc in
the absence of ligand. However, Grb2 association with IRS-1 could not
be detected in the basal or insulin-stimulated states, and
mitogen-activated protein kinase (MAPK) activity could not be
stimulated by insulin, epidermal growth factor, or platelet-derived
growth factor.
E, the insulin
receptor content and its tyrosine phosphorylation were significantly
decreased in IRwt cells chronically stimulated (>24 h)
with insulin. With decreased IRS-1 content, tyrosine phosphorylation of
IRS-1 was decreased by over 75%, leading to decreased IRS-1-associated
PI 3-kinase and Grb2. In addition, Grb2 association with Shc and
activation of MAPK and the p70 S6 kinase were insensitive to insulin
stimulation. By contrast, association of Grb2 with Shc and activation
of MAPK, but not the p70 S6 kinase, could be stimulated by epidermal
growth factor or platelet-derived growth factor. These data suggest
that there are multiple levels of postreceptor desensitization to
insulin action. These are used somewhat differently in these two
different models, probably due in part to the difference in receptor
down-regulation.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
N. Kumar and C. S. Dey Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells J. Exp. Biol., December 1, 2002; 205(23): 3739 - 3746. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Lee, J. L. Gooch, S. Oesterreich, R. L. Guler, and D. Yee Insulin-Like Growth Factor I-Induced Degradation of Insulin Receptor Substrate 1 Is Mediated by the 26S Proteasome and Blocked by Phosphatidylinositol 3'-Kinase Inhibition Mol. Cell. Biol., March 1, 2000; 20(5): 1489 - 1496. [Abstract] [Full Text] |
||||
![]() |
T. C. Haddad and C. A. Conover Insulin and Interleukin-4 Induce Desensitization to the Mitogenic Effects of Insulin-like Growth Factor-I. PIVOTAL ROLE FOR INSULIN RECEPTOR SUBSTRATE-2 J. Biol. Chem., August 1, 1997; 272(31): 19525 - 19531. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |